NGM Biopharmaceuticals Inc banner
N

NGM Biopharmaceuticals Inc
F:0IK

Watchlist Manager
NGM Biopharmaceuticals Inc
F:0IK
Watchlist
Price: 3.65 EUR -1.62% Market Closed
Market Cap: €304.6m

Relative Value

The Relative Value of one 0IK stock under the Base Case scenario is hidden EUR. Compared to the current market price of 3.65 EUR, NGM Biopharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0IK Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

0IK Competitors Multiples
NGM Biopharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
NGM Biopharmaceuticals Inc
F:0IK
304.6m EUR 1.4 37.8 12.3 21.9
US
Eli Lilly and Co
NYSE:LLY
932.9B USD 14.3 45.2 30.5 32.5
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
271B CHF 4.4 21 12.4 13.9
CH
Novartis AG
SIX:NOVN
236.2B CHF 5.4 21.8 13.5 17.3
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 5.1 29.5 16.3 23
US
Merck & Co Inc
NYSE:MRK
287.1B USD 4.4 15.7 9.8 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.7 8 9.3
US
Pfizer Inc
NYSE:PFE
153.8B USD 2.5 19.8 7.6 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
121B USD 2.5 17.2 7.2 8.9
P/E Multiple
Earnings Growth PEG
US
N
NGM Biopharmaceuticals Inc
F:0IK
Average P/E: 24
37.8
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
45.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
21
14%
1.5
CH
Novartis AG
SIX:NOVN
21.8
14%
1.6
UK
AstraZeneca PLC
LSE:AZN
29.5
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.7
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.2
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
N
NGM Biopharmaceuticals Inc
F:0IK
Average EV/EBITDA: 43.4
12.3
18%
0.7
US
Eli Lilly and Co
NYSE:LLY
30.5
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.4
6%
2.1
CH
Novartis AG
SIX:NOVN
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
16.3
13%
1.3
US
Merck & Co Inc
NYSE:MRK
9.8
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett